A review of the benefit–risk profile of gefitinib in Asian patients with advanced non‐small‐cell lung cancer

Global cancer statistics

2011 • 55,498 citations

Global Cancer Statistics, 2002

2005 • 17,966 citations

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2004 • 11,185 citations

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

2004 • 9,201 citations

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

2004 • 4,293 citations

Cancer incidence, mortality and prevalence worldwide

2004 • 3,893 citations

EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

2005 • 3,807 citations

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

2005 • 3,450 citations

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

2003 • 2,874 citations

Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

2000 • 2,156 citations

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

2005 • 2,102 citations

Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

2000 • 1,359 citations

Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer

2004 • 1,206 citations

Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence

2005 • 965 citations

Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

2005 • 782 citations

Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer

2005 • 704 citations

High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non–Small Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan

2004 • 544 citations

Severe acute interstitial pneumonia and gefitinib

2003 • 445 citations

Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer

2005 • 315 citations

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors

2003 • 271 citations

The epidemiology of interstitial lung disease and its association with lung cancer

2004 • 198 citations

Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib

2004 • 179 citations

Effect of gefitinib (‘Iressa’, ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer

2004 • 178 citations

Predictors of the Response to Gefitinib in Refractory Non–Small Cell Lung Cancer

2005 • 175 citations

Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)

2004 • 174 citations

Interstitial lung disease associated with drug therapy

2004 • 161 citations

Pharmacogenetics for individualized cancer chemotherapy

2005 • 159 citations

Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®, ZD1839) in chemotherapy‐resistant non‐small cell lung cancer

2004 • 156 citations

Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity

2004 • 143 citations

Clinically Meaningful Improvement in Symptoms and Quality of Life for Patients With Non-Small-Cell Lung Cancer Receiving Gefitinib in a Randomized Controlled Trial

2005 • 120 citations

An Interethnic Comparison of Polymorphisms of the Genes Encoding Drug-Metabolizing Enzymes and Drug Transporters: Experience in Singapore

2005 • 109 citations

Diagnosis and management of drug-associated interstitial lung disease

2004 • 102 citations

The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer

2005 • 96 citations

Gefitinib (ZD1839) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer

2004 • 79 citations

Understanding the mechanisms of drug-associated interstitial lung disease

2004 • 74 citations

Interstitial Lung Disease in Japanese Patients With Non-Small Cell Lung Cancer Receiving Gefitinib

2005 • 74 citations

Overview of the Tolerability of Gefitinib (IRESSA???) Monotherapy

2004 • 71 citations

Dominant Papillary Subtype Is a Significant Predictor of the Response to Gefitinib in Adenocarcinoma of the Lung

2004 • 69 citations

Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer

2004 • 59 citations

Acute lung injury as a possible adverse drug reaction related to gefitinib

2002 • 49 citations

Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America

2005 • 47 citations

Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status

2004 • 40 citations

Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic–uremic syndrome due to gemcitabine

2003 • 35 citations

Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme

2004 • 34 citations

Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib

2004 • 30 citations

Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): A model for prospective comparison of cooperative group trials

2004 • 28 citations

Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience

2005 • 28 citations

Interstitial lung diseases (ILD) induced by gefitinib in patients with advanced non-small cell lung cancer (NSCLC): Results of a West Japan Thoracic Oncology Group (WJTOG) epidemiological survey

2004 • 27 citations

[Subset analysis of data in the Japanese patients with NSCLC from IDEAL 1 study on gefitinib].

2004 • 20 citations

A phase II study of gefitinib as a dirst-line therapy of advanced or metastatic adenocarcinoma of the lung in lifetime non-smokers

2005 • 17 citations

[Efficacy of gefitinib on Chinese patients with locally advanced or metastatic non-small cell lung cancer: a clinical trial].

2005 • 14 citations

First-line single agent of gefitinib in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II study

2004 • 12 citations

Association of multiple pulmonary metastases with response to gefitinib in patients with non-small cell lung cancer

2004 • 10 citations

A phase II study of gefitinib monotherapy for chemotherapy-naive patients with non-small cell lung cancer

2005 • 10 citations

Pharmacogenomics in Asia

2004 • 9 citations

EGFR mutations in lung cancers and sensitivity to gefitinib in Chinese

2005 • 8 citations

EGFR and K-ras mutations as determinants of gefitinib sensitivity in non-small-cell lung cancer (NSCLC)

2005 • 7 citations

A phase II study of first-line single agent of gefitinib in patients (pts) with stage IV non-small cell lung cancer (NSCLC)

2005 • 7 citations

ZD1839 for the treatment of heavily pretreated non-small cell lung cancer

2004 • 5 citations

Hypoalbuminemia as a risk factor of interstitial lung disease (ILD) during gefitinib treatment in patients with non-small cell lung cancer (NSCLC): A JMTO study

2005 • 5 citations

Factors predicting the efficacy of gefitinib in patients with advanced non-small cell lung cancer (NSCLC)

2005 • 5 citations

[Iressa for the non-small cell lung cancer patients who failed prior chemotherapy and radiotherapy].

2004 • 4 citations

Effect of epidermal growth factor receptor gene mutations on adverse events of gefitinib in patients with non-small cell lung cancer

2005 • 3 citations

The Efficacy of ZD1839 (Iressa™) in Patients with Advanced Non-small Cell Lung Cancer which has Progressed After Previous Chemotherapy

2004 • 3 citations

Correlation between gefitinib efficacy and HER family expression in recurrent non-small-cell lung cancer (NSCLC)

2004 • 3 citations

Evaluating a prognostic factor in advanced adenocarcinoma of the lung who have treated with gefinitib

2004 • 3 citations

[Iressa for refractory non-small cell lung cancer: A preliminary report].

2004 • 2 citations

The Effect of ZD 1839 (Iressa(R)) in the Treatment of Refractory Non Small Cell Lung Cancer

2003 • 2 citations

[The salvage regimen for patients with advanced non-small cell lung cancer who failed prior chemotherapy: once-daily single oral agent Iressa].

2004 • 1 citations